Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2023022480
Abstract: Key Points • JNJ-75276617 shows preclinical activity in KMT2A- or NPM1-altered leukemia, synergizing with gilteritinib, venetoclax, and azacitidine.• Antiproliferative activity in cells harboring menin mutations M327I and T349M is due to a unique binding mode. read more here.
Keywords: menin; preclinical efficacy; npm1 altered; jnj 75276617 ... See more keywords